Sarcolemmal KATP channel modulators and cardiac arrhythmias

I. Baczkó, Z. Husti, V. Lang, I. Leprán, P. E. Light

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Cardiac atrial and ventricular arrhythmias are major causes of mortality and morbidity. Ischemic heart disease is the most common cause underlying 1) the development of ventricular fibrillation that results in sudden cardiac death and 2) atrial fibrillation that can lead to heart failure and stroke. Current pharmacological agents for the treatment of ventricular and atrial arrhythmias exhibit limited effectiveness and many of these agents can cause serious adverse effects - including the provocation of lethal ventricular arrhythmias. Sarcolemmal ATP-sensitive potassium channels (sarcKATP) couple cellular metabolism to membrane excitability in a wide range of tissues. In the heart, sarcKATP are activated during metabolic stress including myocardial ischemia, and both the opening of sarcKATP and mitochondrial KATP channels protect the ischemic myocardium via distinct mechanisms. Myocardial ischemia leads to a series of events that promote the generation of arrhythmia substrate eventually resulting in the development of life-threatening arrhythmias. In this review, the possible mechanisms of the anti- and proarrhythmic effects of sarcKATP modulation as well as the influence of pharmacological KATP modulators are discussed. It is concluded that in spite of the significant advances made in this field, the possible cardiovascular therapeutic utility of current sarcKATP channel modulators is still hampered by the lack of chamber-specific selectivity. However, recent insights into the chamber-specific differences in the molecular composition of sarcKATP in addition to already existing cardioselective sarcKATP channel modulators with sarcKATP isoform selectivity holds the promise for the future development of pharmacological strategies specific for a variety of atrial and ventricular arrhythmias.

Original languageEnglish
Pages (from-to)3640-3661
Number of pages22
JournalCurrent Medicinal Chemistry
Volume18
Issue number24
DOIs
Publication statusPublished - Aug 2011

Fingerprint

KATP Channels
Modulators
Cardiac Arrhythmias
Myocardial Ischemia
Pharmacology
Metabolism
Protein Isoforms
Modulation
Tissue
Membranes
Physiological Stress
Sudden Cardiac Death
Ventricular Fibrillation
Substrates
Chemical analysis
Atrial Fibrillation
Myocardium
Heart Failure
Stroke
Morbidity

Keywords

  • ATP-sensitive potassium channel
  • Atrial fibrillation
  • Cardiac arrhythmias
  • K channel blockers
  • Mitochondrial K channel
  • Potassium channel openers
  • Repolarization
  • Reverse use-dependent prolongation of repolarization
  • Sarcolemmal K channel

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Sarcolemmal KATP channel modulators and cardiac arrhythmias. / Baczkó, I.; Husti, Z.; Lang, V.; Leprán, I.; Light, P. E.

In: Current Medicinal Chemistry, Vol. 18, No. 24, 08.2011, p. 3640-3661.

Research output: Contribution to journalArticle

Baczkó, I. ; Husti, Z. ; Lang, V. ; Leprán, I. ; Light, P. E. / Sarcolemmal KATP channel modulators and cardiac arrhythmias. In: Current Medicinal Chemistry. 2011 ; Vol. 18, No. 24. pp. 3640-3661.
@article{260e7a656cd140d5997e3240ac7e2b65,
title = "Sarcolemmal KATP channel modulators and cardiac arrhythmias",
abstract = "Cardiac atrial and ventricular arrhythmias are major causes of mortality and morbidity. Ischemic heart disease is the most common cause underlying 1) the development of ventricular fibrillation that results in sudden cardiac death and 2) atrial fibrillation that can lead to heart failure and stroke. Current pharmacological agents for the treatment of ventricular and atrial arrhythmias exhibit limited effectiveness and many of these agents can cause serious adverse effects - including the provocation of lethal ventricular arrhythmias. Sarcolemmal ATP-sensitive potassium channels (sarcKATP) couple cellular metabolism to membrane excitability in a wide range of tissues. In the heart, sarcKATP are activated during metabolic stress including myocardial ischemia, and both the opening of sarcKATP and mitochondrial KATP channels protect the ischemic myocardium via distinct mechanisms. Myocardial ischemia leads to a series of events that promote the generation of arrhythmia substrate eventually resulting in the development of life-threatening arrhythmias. In this review, the possible mechanisms of the anti- and proarrhythmic effects of sarcKATP modulation as well as the influence of pharmacological KATP modulators are discussed. It is concluded that in spite of the significant advances made in this field, the possible cardiovascular therapeutic utility of current sarcKATP channel modulators is still hampered by the lack of chamber-specific selectivity. However, recent insights into the chamber-specific differences in the molecular composition of sarcKATP in addition to already existing cardioselective sarcKATP channel modulators with sarcKATP isoform selectivity holds the promise for the future development of pharmacological strategies specific for a variety of atrial and ventricular arrhythmias.",
keywords = "ATP-sensitive potassium channel, Atrial fibrillation, Cardiac arrhythmias, K channel blockers, Mitochondrial K channel, Potassium channel openers, Repolarization, Reverse use-dependent prolongation of repolarization, Sarcolemmal K channel",
author = "I. Baczk{\'o} and Z. Husti and V. Lang and I. Lepr{\'a}n and Light, {P. E.}",
year = "2011",
month = "8",
doi = "10.2174/092986711796642472",
language = "English",
volume = "18",
pages = "3640--3661",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "24",

}

TY - JOUR

T1 - Sarcolemmal KATP channel modulators and cardiac arrhythmias

AU - Baczkó, I.

AU - Husti, Z.

AU - Lang, V.

AU - Leprán, I.

AU - Light, P. E.

PY - 2011/8

Y1 - 2011/8

N2 - Cardiac atrial and ventricular arrhythmias are major causes of mortality and morbidity. Ischemic heart disease is the most common cause underlying 1) the development of ventricular fibrillation that results in sudden cardiac death and 2) atrial fibrillation that can lead to heart failure and stroke. Current pharmacological agents for the treatment of ventricular and atrial arrhythmias exhibit limited effectiveness and many of these agents can cause serious adverse effects - including the provocation of lethal ventricular arrhythmias. Sarcolemmal ATP-sensitive potassium channels (sarcKATP) couple cellular metabolism to membrane excitability in a wide range of tissues. In the heart, sarcKATP are activated during metabolic stress including myocardial ischemia, and both the opening of sarcKATP and mitochondrial KATP channels protect the ischemic myocardium via distinct mechanisms. Myocardial ischemia leads to a series of events that promote the generation of arrhythmia substrate eventually resulting in the development of life-threatening arrhythmias. In this review, the possible mechanisms of the anti- and proarrhythmic effects of sarcKATP modulation as well as the influence of pharmacological KATP modulators are discussed. It is concluded that in spite of the significant advances made in this field, the possible cardiovascular therapeutic utility of current sarcKATP channel modulators is still hampered by the lack of chamber-specific selectivity. However, recent insights into the chamber-specific differences in the molecular composition of sarcKATP in addition to already existing cardioselective sarcKATP channel modulators with sarcKATP isoform selectivity holds the promise for the future development of pharmacological strategies specific for a variety of atrial and ventricular arrhythmias.

AB - Cardiac atrial and ventricular arrhythmias are major causes of mortality and morbidity. Ischemic heart disease is the most common cause underlying 1) the development of ventricular fibrillation that results in sudden cardiac death and 2) atrial fibrillation that can lead to heart failure and stroke. Current pharmacological agents for the treatment of ventricular and atrial arrhythmias exhibit limited effectiveness and many of these agents can cause serious adverse effects - including the provocation of lethal ventricular arrhythmias. Sarcolemmal ATP-sensitive potassium channels (sarcKATP) couple cellular metabolism to membrane excitability in a wide range of tissues. In the heart, sarcKATP are activated during metabolic stress including myocardial ischemia, and both the opening of sarcKATP and mitochondrial KATP channels protect the ischemic myocardium via distinct mechanisms. Myocardial ischemia leads to a series of events that promote the generation of arrhythmia substrate eventually resulting in the development of life-threatening arrhythmias. In this review, the possible mechanisms of the anti- and proarrhythmic effects of sarcKATP modulation as well as the influence of pharmacological KATP modulators are discussed. It is concluded that in spite of the significant advances made in this field, the possible cardiovascular therapeutic utility of current sarcKATP channel modulators is still hampered by the lack of chamber-specific selectivity. However, recent insights into the chamber-specific differences in the molecular composition of sarcKATP in addition to already existing cardioselective sarcKATP channel modulators with sarcKATP isoform selectivity holds the promise for the future development of pharmacological strategies specific for a variety of atrial and ventricular arrhythmias.

KW - ATP-sensitive potassium channel

KW - Atrial fibrillation

KW - Cardiac arrhythmias

KW - K channel blockers

KW - Mitochondrial K channel

KW - Potassium channel openers

KW - Repolarization

KW - Reverse use-dependent prolongation of repolarization

KW - Sarcolemmal K channel

UR - http://www.scopus.com/inward/record.url?scp=80052004018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052004018&partnerID=8YFLogxK

U2 - 10.2174/092986711796642472

DO - 10.2174/092986711796642472

M3 - Article

VL - 18

SP - 3640

EP - 3661

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 24

ER -